The DOI matches its Crossref record; 111 of the 111 references it cites were found in a registry or an index.
Stem cell treatment for acute myocardial infarction
Open accessAbstract
BACKGROUND: Cell transplantation offers a potential therapeutic approach to the repair and regeneration of damaged vascular and cardiac tissue after acute myocardial infarction (AMI). This has resulted in multiple randomised controlled trials (RCTs) across the world. OBJECTIVES: To determine the safety and efficacy of autologous adult bone marrow stem cells as a treatment for acute myocardial infarction (AMI), focusing on clinical outcomes. SEARCH METHODS: This Cochrane review is an update of a previous version (published in 2012). We searched the Cochrane Central Register of Controlled Trials (CENTRAL 2015, Issue 2), MEDLINE (1950 to March 2015), EMBASE (1974 to March 2015), CINAHL (1982 to March 2015) and the Transfusion Evidence Library (1980 to March 2015). In addition, we searched several international and ongoing trial databases in March 2015 and handsearched relevant conference proceedings to January 2011. SELECTION CRITERIA: RCTs comparing autologous bone marrow-derived cells with no cells in patients diagnosed with AMI were eligible. DATA COLLECTION AND ANALYSIS: Two review authors independently screened all references, assessed the risk of bias of the included trials and extracted data. We conducted meta-analyses using random-effects models throughout. We analysed outcomes at short-term (less than 12 months) and long-term (12 months or more) follow-up. Dichotomous outcomes are reported as risk ratio (RR) and continuous outcomes are reported as mean difference (MD) or standardised MD (SMD). We performed sensitivity analyses to evaluate the results in the context of the risk of selection, performance and attrition bias. Exploratory subgroup analysis investigated the effects of baseline cardiac function (left ventricular ejection fraction, LVEF) and cell dose, type and timing of administration, as well as the use of heparin in the final cell solution. MAIN RESULTS: Forty-one RCTs with a total of 2732 participants (1564 cell therapy, 1168 controls) were eligible for inclusion. Cell treatment was not associated with any changes in the risk of all-cause mortality (34/538 versus 32/458; RR 0.93, 95% CI 0.58 to 1.50; 996 participants; 14 studies; moderate quality evidence), cardiovascular mortality (23/277 versus 18/250; RR 1.04, 95% CI 0.54 to 1.99; 527 participants; nine studies; moderate quality evidence) or a composite measure of mortality, reinfarction and re-hospitalisation for heart failure (24/262 versus 33/235; RR 0.63, 95% CI 0.36 to 1.10; 497 participants; six studies; moderate quality evidence) at long-term follow-up. Statistical heterogeneity was low (I(2) = 0% to 12%). Serious periprocedural adverse events were rare and were generally unlikely to be related to cell therapy. Additionally, cell therapy had no effect on morbidity, quality of life/performance or LVEF measured by magnetic resonance imaging. Meta-analyses of LVEF measured by echocardiography, single photon emission computed tomography and left ventricular angiography showed evidence of differences in mean LVEF between treatment groups although the mean differences ranged between 2% and 5%, which are accepted not to be clinically relevant. Results were robust to the risk of selection, performance and attrition bias from individual studies. AUTHORS' CONCLUSIONS: The results of this review suggest that there is insufficient evidence for a beneficial effect of cell therapy for AMI patients. However, most of the evidence comes from small trials that showed no difference in clinically relevant outcomes. Further adequately powered trials are needed and until then the efficacy of this intervention remains unproven.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Measuring inconsistency in meta-analyses
Higgins, J. P. T., Thompson, S. G., Deeks, J. J., & Altman, D. G. (2003) · BMJ · doi:10.1136/bmj.327.7414.557 · Cited by 63,139
Bias in meta-analysis detected by a simple, graphical test
Egger, M., Smith, G. D., Schneider, M., & Minder, C. (1997) · BMJ · doi:10.1136/bmj.315.7109.629 · Cited by 56,722
Bone marrow cells regenerate infarcted myocardium
Orlic, D., Kajstura, J., Chimenti, S., Jakoniuk, I., Anderson, S. M., Li, B., Pickel, J., McKay, R., Nadal-Ginard, B., Bodine, D. M., et al. (2001) · Nature · doi:10.1038/35070587 · Cited by 5,155
Falk, E., Shah, P. K., & Fuster, V. (1995) · Circulation · doi:10.1161/01.cir.92.3.657 · Cited by 3,536
Assessing the quality of controlled clinical trials
Jüni, P., Altman, D. G., & Egger, M. (2001) · BMJ · doi:10.1136/bmj.323.7303.42 · Cited by 3,309
Human Mesenchymal Stem Cells Differentiate to a Cardiomyocyte Phenotype in the Adult Murine Heart
Toma, C., Pittenger, M. F., Cahill, K. S., Byrne, B. J., & Kessler, P. D. (2002) · Circulation · doi:10.1161/hc0102.101442 · Cited by 2,234
Assmus, B., Schächinger, V., Teupe, C., Britten, M., Lehmann, R., Döbert, N., Grünwald, F., Aicher, A., Urbich, C., Martin, H., et al. (2002) · Circulation · doi:10.1161/01.cir.0000043246.74879.cd · Cited by 2,201
Wollert, K. C., Meyer, G. P., Lotz, J., Ringes Lichtenberg, S., Lippolt, P., Breidenbach, C., Fichtner, S., Korte, T., Hornig, B., Messinger, D., et al. (2004) · The Lancet · doi:10.1016/s0140-6736(04)16626-9 · Cited by 2,191
Mobilized bone marrow cells repair the infarcted heart, improving function and survival
Orlic, D., Kajstura, J., Chimenti, S., Limana, F., Jakoniuk, I., Quaini, F., Nadal-Ginard, B., Bodine, D. M., Leri, A., & Anversa, P. (2001) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.181177898 · Cited by 2,086
Cited by
Arslan, F., Lai, R. C., Smeets, M. B., Akeroyd, L., Choo, A., Aguor, E. N. E., Timmers, L., van Rijen, H. V., Doevendans, P. A., Pasterkamp, G., et al. (2013) · Stem Cell Research · doi:10.1016/j.scr.2013.01.002 · Cited by 1,107
The war against heart failure: the Lancet lecture
Braunwald, E. (2015) · The Lancet · doi:10.1016/s0140-6736(14)61889-4 · Cited by 811
Inflammation as a Driver of Adverse Left Ventricular Remodeling After Acute Myocardial Infarction
Westman, P. C., Lipinski, M. J., Luger, D., Waksman, R., Bonow, R. O., Wu, E., & Epstein, S. E. (2016) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2016.01.073 · Cited by 506
Gyöngyösi, M., Wojakowski, W., Lemarchand, P., Lunde, K., Tendera, M., Bartunek, J., Marban, E., Assmus, B., Henry, T. D., Traverse, J. H., et al. (2015) · Circulation Research · doi:10.1161/circresaha.116.304346 · Cited by 313
Dechartres, A., Boutron, I., Trinquart, L., Charles, P., & Ravaud, P. (2011) · Annals of Internal Medicine · doi:10.7326/0003-4819-155-1-201107050-00006 · Cited by 307
Metadata
- Authors
- Fisher, S. A., Zhang, H., Doree, C., Mathur, A., & Martin-Rendon, E.
- Venue
- Cochrane Database of Systematic Reviews
- Publisher
- Wiley
- Published
- 2015-09-30
- Volume
- 2015
- Issue
- 9
- Pages
- CD006536-CD006536
- ISSN
- 1361-6137 (ISSN-L)
- 1465-1858
- OpenAlex
- W2097393280
- Cited by
- 445
- References
- 111
- FWCI
- 28.04
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Stem cell treatment for acute myocardial infarction. https://app.cochat.ai/papers/10.1002/14651858.cd006536.pub4
- The paper
- Fisher, S. A., Zhang, H., Doree, C., Mathur, A., & Martin-Rendon, E. (2015). Stem cell treatment for acute myocardial infarction. Cochrane Database of Systematic Reviews. https://doi.org/10.1002/14651858.cd006536.pub4
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.